Konkurencja i konsument · 02/08/1995
Glaxo plc Agrees to Divest Assets and Obtain Commission Approval for Migraine Drug Acquisitions
Glaxo plc has agreed to settle allegations of prohibited trade practices by divesting Wellcome's non-injectable drug research and development assets within nine months, and obtaining Commission approval for future acquisitions of migraine drug entities for ten years.